For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Neorx Corporation

USPTO Granted Patents = 156

% Expired Patents = 8.3

CIPO Patents = 1

Forward Citations = 6,549

Loading Chart...

Loading Chart...

69 inventors (with patents filed for the assignee):

Alan R Fritzberg (44 out of 53 patents)

Sudhakar Kasina (38 out of 50 patents)

John M Reno (36 out of 45 patents)

4. Ananthachari Srinivasan (33 out of 48 patents)

5. David John Grainger (20 out of 42 patents)

6. Linda M Gustavson (20 out of 32 patents)

7. James C Metcalfe (18 out of 20 patents)

8. Louis J Theodore (17 out of 23 patents)

9. Paul G Abrams (15 out of 19 patents)

10. Lawrence L Kunz (15 out of 17 patents)

11. Donald B Axworthy (13 out of 15 patents)

12. Daniel S Wilbur (13 out of 13 patents)

13. Peter L Weissberg (12 out of 13 patents)

14. Mark D Hylarides (9 out of 12 patents)

15. A Charles Morgan, Jr (9 out of 15 patents)

Core Competencies:

Radiolabeled Annexins

Radionuclide Complexes

Targeting Protein-Diagnostic Conjugates

Therapeutic Inhibitors

Pretargeting Methods

Cardiovascular Pathologies

Biotin-DOTA Conjugates

Aromatic Amine Ligands

Hepatic-Directed Compounds

Nitro-Benzyl-DOTA

Small Molecular Weight Ligands

Chelating Compounds

156 patents: Sort by Forward Citations

1. 7115720 - Therapeutic and diagnostic compounds, compositions, and methods (2006-10-03),

2. 7115248 - Radiolabeled annexins (2006-10-03),

3. 7097823 - High dose radionuclide complexes for bone marrow suppression (2006-08-29),

4. 7094885 - Skeletal-targeted radiation to treat bone-associated pathologies (2006-08-22),

5. 7094550 - Method to determine TGF-beta (2006-08-22),

6. 7084171 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2006-08-01),

7. 7070759 - High dose radionuclide complexes for bone marrow suppression (2006-07-04),

8. 6936700 - Bridged aromatic substituted amine ligands with donor atoms (2005-08-30),

9. 6767531 - High dose radionuclide complexes for bone marrow suppression (2004-07-27),

10. 6734208 - Compounds and therapies for the prevention of vascular and non-vascular pathologies (2004-05-11),

11. 6709652 - Pretargeting methods and compounds (2004-03-23),

12. 6663881 - Therapeutic inhibitor of vascular smooth muscle cells (2003-12-16),

13. 6599928 - Therapeutic inhibitor of vascular smooth muscle cells (2003-07-29),

14. 6569441 - Therapeutic inhibitor of vascular smooth muscle cells (2003-05-27),

15. 6534037 - Non-steroidal compounds for steroid receptors and uses relating thereto (2003-03-18),

NeoRx Corporation is a biopharmaceutical company focused on the development of targeted radiopharmaceuticals for the treatment of cancer and other serious diseases. Their innovative approach combines the power of radiation therapy with specific targeting agents to deliver precise, localized treatment directly to cancer cells while minimizing damage to healthy tissues. With a strong commitment to improving patient outcomes, NeoRx Corporation continues to advance their pipeline of novel radiopharmaceuticals, striving to make a meaningful impact in the lives of patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Neorx Corporation

156 Patents

#15 in Seattle, WA

#50 in Washington

#2,534 in US

#5,242 in the World

Seattle, WA, United States of America

Neorx Corporation

Forward Citations = 6,549

69 inventors:

Alan R Fritzberg (44 out of 53 patents)

Sudhakar Kasina (38 out of 50 patents)

John M Reno (36 out of 45 patents)

4. Ananthachari Srinivasan (33 out of 48 patents)

5. David John Grainger (20 out of 42 patents)

Please report any incorrect information to [email protected]

Loading…